

# natureOUTLOOK

## LYMPHOMA

15 November 2018 / Vol 563 / Issue No 7731



Cover art: Ana Kova

### Editorial

Herb Brody,  
Richard Hodson,  
Elizabeth Batty,  
Lewis Packwood

### Art & Design

Mohamed Ashour,  
Wesley Fernandes,  
Kate Duncan,  
Denis Mallet

### Production

Nick Bruni, Karl  
Smart, Ian Pope

### Sponsorship

David Bagshaw,  
Anushree Roy

### Marketing

Nicole Jackson

### Project Manager

Rebecca Jones

### Creative Director

Wojtek Urbanek

### Publisher

Richard Hughes

### Editorial Director

Stephen Pincock

### Magazine Editor

Helen Pearson

### Editor-in-Chief

Magdalena Skipper

Ordinarily, our immune system protects us from harm. In lymphoma, however, elements of it turn against us and become a malignant force. Therapy for one form of the disease, Hodgkin's lymphoma, can be considered a success story: improvements in treatment mean that about 85% of people now survive for at least five years after diagnosis. For other forms of the disease, such as non-Hodgkin's lymphoma, the outlook for patients is bleaker. But research is deepening our understanding of all forms of this class of cancer, and seeding hopes of more effective therapies.

Before a disease can be treated, it must first be diagnosed. The advent of liquid biopsies that detect small pieces of tumour DNA circulating in the blood is bringing greater precision to this task: circulating DNA can indicate both the tumour's size and the mutations behind it (see page S38).

The standard, reasonably successful treatments for lymphoma are chemo- and radiotherapy. But for some people, these therapies will lead to heart problems and other forms of cancer later in life (S44). Fortunately, an array of new treatments are in development, guided in part by work with a strikingly good animal model of the human disease: dogs (S50).

Researchers are developing a gene-modifying treatment called chimeric antigen receptor T-cell therapy, in which a person's immune system is altered to seek and destroy tumour cells (S42). And drugs known as Bruton's tyrosine kinase inhibitors are emerging: these block a molecule in the signalling pathway that turns some white blood cells cancerous (S46). Work is also under way to craft vaccines against lymphomas (S52), and progress in treating graft-versus-host disease could open the door to more options for stem-cell therapy (S48).

We are pleased to acknowledge the financial support of F. Hoffmann-La Roche in producing this Outlook. As always, *Nature* has sole responsibility for all editorial content.

### Herb Brody

*Chief supplements editor*

## CONTENTS

### S38 DIAGNOSTICS

#### Know thy enemy

Liquid biopsies could give almost real-time information on cancer burden

### S42 IMMUNOTHERAPY

#### Gene therapy delivers hope

Chimeric antigen receptor T-cell therapy offers a final shot at a cure

### S44 THERAPY

#### The cost of beating cancer

Why children who survive lymphoma could face further battles

### S46 THERAPEUTICS

#### A life-changing innovation

Targeted drugs have revolutionized lymphoma treatment

### S48 STEM CELLS

#### Painful rejection

Tackling graft-versus-host disease could make stem-cell transplants more viable

### S50 ANIMAL MODELS

#### The model dog

Canine lymphoma is remarkably similar to the human disease

### S52 IMMUNOLOGY

#### Dormant but dangerous

The almost ubiquitous Epstein-Barr virus has been linked to various cancers

### S55 LYMPHOMA

#### 4 big questions

The challenges that still lie ahead

*Nature Outlooks* are sponsored supplements that aim to stimulate interest and debate around a subject of interest to the sponsor, while satisfying the editorial values of *Nature* and our readers' expectations. The boundaries of sponsor involvement are clearly delineated in the *Nature Outlook* Editorial guidelines available at [go.nature.com/e4dwzw](http://go.nature.com/e4dwzw)

#### CITING THE OUTLOOK

Cite as a supplement to *Nature*, for example, *Nature* Vol. XXX, No. XXXX Suppl., Sxx–Sxx (2018).

#### VISIT THE OUTLOOK ONLINE

The *Nature Outlook Lymphoma* supplement can be found at [www.nature.com/collections/lymphoma-outlook](http://www.nature.com/collections/lymphoma-outlook). It features all newly commissioned content as well as a selection of relevant previously published material that is made freely

available for 6 months.

#### SUBSCRIPTIONS AND CUSTOMER SERVICES

Site licences ([www.nature.com/libraries/site\\_licences](http://www.nature.com/libraries/site_licences)): Americas, [institutions@natureny.com](mailto:institutions@natureny.com); Asia-Pacific, <http://nature.asia/jp-contact>; Australia/New Zealand, [nature@macmillan.com.au](mailto:nature@macmillan.com.au); Europe/ROW, [institutions@nature.com](mailto:institutions@nature.com); India, [npgindia@nature.com](mailto:npgindia@nature.com). Personal subscriptions: UK/Europe/ROW, [subscriptions@nature.com](mailto:subscriptions@nature.com); USA/Canada/Latin America, [subscriptions@us.nature.com](mailto:subscriptions@us.nature.com); Japan, <http://nature.asia/jp-contact>; China, <http://nature.asia/china-subscribe>; Korea, [www.natureasia.com/ko-kr/subscribe](http://www.natureasia.com/ko-kr/subscribe).

#### CUSTOMER SERVICES

[Feedback@nature.com](mailto:Feedback@nature.com)

Copyright © 2018 Springer Nature Ltd. All rights reserved.